Nalaganje...
Overcoming imatinib resistance conferred by the BIM deletion polymorphism in chronic myeloid leukemia with splice-switching antisense oligonucleotides
Many tyrosine kinase-driven cancers, including chronic myeloid leukemia (CML), are characterized by high response rates to specific tyrosine kinase inhibitors (TKIs) like imatinib. In East Asians, primary imatinib resistance is caused by a deletion polymorphism in Intron 2 of the BIM gene, whose pro...
Shranjeno v:
| izdano v: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Impact Journals LLC
2017
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5652800/ https://ncbi.nlm.nih.gov/pubmed/29100409 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.20658 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|